Biodesix Reports Impressive 45% Revenue Growth in 2024
AInvestFriday, Jan 10, 2025 6:06 am ET
1min read
BDSX --


Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, has announced preliminary, unaudited results for the fourth quarter and full-year 2024, showcasing remarkable financial momentum. Total revenue reached an estimated $71.3 million for 2024, marking a 45% increase year-over-year, with Q4 revenue at $20.4 million, up 39%. This significant growth is driven by both core segments, with Lung Diagnostics contributing $64.7 million (up 43%) and Biopharma Services exhibiting exceptional growth of 69%.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.